Asna Latif is The Journal of Pharmacology and Experimental Therapeutics Highlighted Trainee Author for February 2025. Asna is a PhD Candidate at the University of Alberta. 

The JPET article that earned him the selection of Highlighted Trainee Author is titled “TLR4 downregulation protects against cisplatin-induced ototoxicity in adult and pediatric patients with cancer” and is available at: https://doi.org/10.1016/j.jpet.2024.100057. 

Her research addresses the role of pharmacogenomics in cancer therapy, specifically the development of hearing loss due to cisplatin treatment. Asna hopes that through this work, she and her research team have contributed to justifying the importance of an individual’s genetic makeup in their responses to drugs and identified ways in which therapy options can be improved by implementing other diagnostic tools that may be able to predict toxicity to cisplatin chemotherapy.